Abstract
A 51-year-old male was diagnosed with an IgA multiple myeloma (MM) after having back pain for several months. His bone marrow showed 30% involvement with plasma cells and his cytogenetics showed t(4:14). His beta2-microglobulin was 6.5 mg/dL at diagnosis and he had multiple lytic lesions, along with a creatinine of 2.3 mg/dL and significant anemia. Induction therapy with lenalidomide, bortezomib and dexamethasone was used, and he was able to achieve complete remission after 4 cycles of therapy. He then went on to receive high-dose chemotherapy with a single autologous stem cell transplant. He tolerated it well and now comes to discuss follow-up treatment plans. He wants to discuss maintenance therapy.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Boronic Acids / administration & dosage
-
Bortezomib
-
Clinical Trials as Topic / statistics & numerical data
-
Combined Modality Therapy
-
Dexamethasone / administration & dosage
-
Evidence-Based Medicine
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Immunologic Factors / therapeutic use
-
Interferon-alpha / administration & dosage
-
Lenalidomide
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / surgery
-
Practice Guidelines as Topic*
-
Pyrazines / administration & dosage
-
Randomized Controlled Trials as Topic / statistics & numerical data
-
Remission Induction
-
Thalidomide / administration & dosage
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
Substances
-
Boronic Acids
-
Immunologic Factors
-
Interferon-alpha
-
Pyrazines
-
Thalidomide
-
Bortezomib
-
Dexamethasone
-
Lenalidomide